Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
Authors
Pujol, JPirker, R
Lynch, T
Butts, C
Rosell, R
Shepherd, F
Vansteenkiste, J
O'Byrne, K
de Blas, B
Heighway, J
von Heydebreck, A
Thatcher, Nick
Affiliation
Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, FranceIssue Date
2014-02
Metadata
Show full item recordAbstract
Four randomized phase II/III trials investigated the addition of cetuximab to platinum-based, first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). A meta-analysis was performed to examine the benefit/risk ratio for the addition of cetuximab to chemotherapy.Citation
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. 2014, 83 (2):211-8 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2013.11.006PubMed ID
24332319Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2013.11.006